Which screening test is recommended for women aged 30-65 for cervical cancer?

The recommendation for cervical cancer screening in women aged 30-65 is to use Pap and HPV co-testing. This dual approach is crucial because it combines the benefits of both tests to enhance the detection of cervical precancerous lesions and cancers.

The Pap smear, which examines the cells of the cervix for abnormalities, has been a long-standing method for cervical cancer screening. However, the HPV test, which detects the presence of high-risk strains of the human papillomavirus that can lead to cervical cancer, provides valuable complementary information. The co-testing allows for a more comprehensive assessment of a woman’s cervical health, as it identifies potential risks that might not be evident with either test alone.

Furthermore, screening with both tests can extend the interval between screenings. Women who have normal results from both tests may only need to be screened every five years, compared to more frequent screening if only one of the tests is performed. This aligns with current guidelines and provides a more effective and efficient strategy for early detection and prevention of cervical cancer.

In contrast, screening methods like the ultrasound examination, while useful for other gynecological assessments, are not recommended specifically for cervical cancer screening. Focusing solely on either the Pap smear or the HPV test without the integration of both misses